Atriva Therapeutics GmbH

Atriva Therapeutics GmbH develops biopharmaceutical therapies for severe respiratory viral infections. The Company advances clinical research and host- cell-targeting antiviral treatments for illnesses such as influenza, dengue, and hanta. Atriva Therapeutics serves hospitals and healthcare providers in Europe, Germany, and Canada.